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ADDICTION LIVES: DENNIS MCCARTY 
[PHOTO] 
 
Addiction Lives records the views and personal experiences of people who have especially contributed 
to the evolution of ideas in addiction science. To suggest an interviewee, send a statement of up to 
50 words summarising the person’s exceptional contribution to the field to the Addiction Lives Editor: 
Prof Virginia Berridge, Centre for History in Public Health, London School of Hygiene and Tropical 
Medicine, 15-17 Tavistock Place, London WC1 H 9SH, tel +44 (0)207  927 2269, email 
Virginia.Berridge@lshtm.ac.uk. 
 
INTERVIEW SUMMARY BY VIRGINIA BERRIDGE 
Dennis McCarty grew up in an Irish Catholic neighbourhood in Louisville Kentucky. His parents and 
friends were what would now be termed heavy drinkers. His first involvement with drug and alcohol 
research came in 1975 as a University of Kentucky graduate student in psychology when he accepted 
a graduate research assistant post assessing the effectiveness of outpatient care for alcohol use 
disorders. That graduate school experience led to post-doctoral study at the University of North 
Carolina Centre for Alcohol Studies with John Ewing and Ken Mills. He received his first research 
award from the North Carolina Alcoholism Research Authority to study misattribution of alcohol 
intoxication; he also directed an evaluation of prevention services. 
He moved to Boston in 1980, and collaborated with Milton Argeriou on research contracts for the 
Massachusetts Department of Public Health, creating a small non-profit corporation to accept the 
contracts.  He became Deputy Director for Policy and Evaluation in the newly formed Bureau of 
Substance Abuse Services in 1987. Michael Dukakis’ presidential campaign in 1987/88 provided the 
opportunity to expand Massachusetts Medicaid coverage to include outpatient services for alcohol 
and drug use. In 1989, Governor Dukakis appointed David Mulligan Commissioner of Public Health 
and McCarty became Director of Substance Abuse Services.  
He was involved in the Massachusetts MOTHERS (Medicaid Opportunities to Help Enter Recovery 
Services) programme and also in SHARE (Sober Homes for Addiction Recovery Environments) loan 
programme. When state funding for drug and alcohol services was drastically cut in the early 1990’s, 
he developed a consensus with providers that prioritised services for women, minorities and people 
with HIV or at risk from HIV through injecting drugs. 
Because of his experience with Medicaid, health policy and a history of NIH awards, the Institute for 
Health Policy at Brandeis University offered him a position in 1995. 14 years of work in the 
Massachusetts department and experience with Medicaid managed care provided insights into 
financing and managing service systems and the foundation for his academic work at Brandeis and 
Oregon Health and Science University. 
In September 1995, he received an award from the National Institute on Drug Abuse (NIDA) to 
develop health services research on treatment for drug use disorders. He was asked to join an 
Institute of Medicine committee and was co-editor of its report Managing Managed Care: Quality 
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Improvement in Behavioural Health (1997).This service led to appointment to a second IoM 
committee, the committee on community based drug treatment. Its first recommendation was that 
NIDA should support a practice based research network to test emerging behavioural and 
pharmacotherapies in the chaos of clinical practice. He co-edited the report with Mitch Greenlick, its 
chair and Sarah Lamb, committee director. Mitch recruited him to Oregon Health and Science 
University in 2000. 
He worked with process engineer Dave Gustafson from the University of Wisconsin on a Robert 
Woods Johnson award initially named Paths to Recovery, now identified as NIATx (originally the 
Network for the Improvement of Addiction Treatment). An extension of the model called Advancing 
Recovery used partnerships between payers and their publicly funded treatment providers to 
promote evidence-based practices. The NIATx enterprise has been the most productive of McCarty’s 
career. 
The opioid epidemic and the use of medication to support recovery has been another substantial 
area of work. The field’s reluctance to use medication to support recovery has been a challenging 
issue to resolve. In Massachusetts, the Bureau supported methadone vans to circumvent community 
opposition. At Brandeis, he participated in one of the early studies assessing the adoption of 
naltrexone; he also assessed the adoption of buprenorphine in speciality addiction treatment 
centres. 
David Mulligan, with whom he worked in Massachusetts, had the most influence on his career. He 
was a former Catholic priest who had served as a missionary in Bolivia. From him, he learnt how to 
run meetings effectively, setting limits and moving agendas. He particularly remembers how 
Mulligan operated to defuse opposition to open a methadone centre in Brockton.  
He sees many emerging health service research opportunities available using innovative tools and 
methods, for example mobile health technologies, using electronic health records to support 
screening and brief interventions and also using the tools of addiction health services research to 
address other non-communicable disorders such as hypertension and diabetes. 
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These analyses documented the safety and effectiveness of an opioid detoxification taper using 
buprenorphine within 12 specialty addiction treatment settings (n = 234). The first multi-site test 
of buprenorphine within specialty clinics. Encouraged adoption of buprenorphine for 
detoxification from opioid use disorders. CTN-0001 and CTN-0002. 
Humphreys, K., Wing, S., McCarty, D., Chappel, J., Gallant, L., Haberle, B., Horvath, A. T., Kaskutas, L. 
A., Kirk, T., Kivlahan, D., Laudet, A., McCrady, B. S., McLellan, A. T., Morgenstern, J., Townsend, M. 
& Weiss, R. (2004).  Self-help organizations for alcohol and drug problems: Toward evidence-
based practice and policy.  Journal of Substance Abuse Treatment, 26, 151 – 158. PMID: 
15063905;  
This consensus statement developed by a Substance Abuse and Mental Health Services 
Administration workgroup reviews the effectiveness of self-help services and the implications for 
stakeholders, consumers, and policy makers. The analysis encourages development of policies 
that support self-help participation including the adoption of validated referral strategies and 
menus of the local options for self-help services. The paper continues to be cited.  
Institute of Medicine (1998). Lamb, S., Greenlick, M. R. & McCarty, D. (Eds.).  Bridging the Gap between 
Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment.  
Washington, DC: National Academy Press. 
The Center for Substance Abuse Treatment and the National Institute on Drug Abuse sponsored 
the Institute of Medicine’s Committee on Community-based Drug Treatment to examine a) 
treatment strategies, promising research approaches and ways to link treatment with research,  
b) mechanisms for treatment programs to participate in research and the adoption of the 
research in practice, c) technology transfer strategies, d) barriers that inhibit research within and 
the application of research to treatment practices, e) barriers that slow integration of treatment 
practices with research and f) innovative strategies to circumvent the barriers. The Committee’s 
first recommendation advocated for development of a community-based clinical trials network 
that tested emerging research in the complexity of real-world addiction treatment settings. The 
recommendations supported the National Institute on Drug Abuse’s creation of the National Drug 
Abuse Treatment Clinical Trials Network. 
McCarty, D., Gustafson, D.H., Wisdom, J.P., Ford, J., Choi, D., Molfenter, T., Capoccia, V., Cotter, F. 
(2007).  The Network for the Improvement of Addiction Treatment (NIATx): Enhancing access and 
retention.  Drug and Alcohol Dependence, 88, 138 - 145.  PMCID: PMC1896099.   
The primary results from the first NIATx demonstration with 13 participating treatment centers 
documented a 37% reduction in days to treatment (from 19.6 to 12.4 days). Retention in care 
improved 18% between the first and second session of care (72% to 85%) and the third session of 
care (62% to 73%). Incremental changes in treatment processes led to reductions in wait times 
and gains in retention. This publication provided a proof of concept that process improvement 
could be applied to addiction treatment services.  
 
